# SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

> **NCT02117167** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 999 (actual)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** AZD2014
- **DRUG:** AZD4547
- **DRUG:** AZD5363
- **DRUG:** AZD8931
- **DRUG:** Selumetinib
- **DRUG:** Vandetanib
- **DRUG:** Standard maintenance for squamous NSCLC
- **DRUG:** Pemetrexed
- **DRUG:** Durvalumab
- **DRUG:** savolitinib
- **DRUG:** Olaparib

## Key facts

- **NCT ID:** NCT02117167
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-23
- **Primary completion:** 2018-12-22
- **Final completion:** 2023-12
- **Target enrollment:** 999 (ACTUAL)
- **Last updated:** 2024-01-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117167, "SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02117167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*